About Tumor-associated calcium signal transducer 2
Tumor-associated calcium signal transducer 2 (TACSTD2) is a protein
from Homo sapiens identified by UniProt accession
P09758, 323 residues long.
MolForge cross-references it against 0 known binders and
305 disease associations.
Target properties
| Protein name | Tumor-associated calcium signal transducer 2 |
| UniProt accession | P09758 |
| Gene | TACSTD2 |
| Organism | Homo sapiens |
| Length | 323 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (305)
Diseases linked to this target (Open Targets).
- gelatinous drop-like corneal dystrophy · score 0.72
- breast cancer · score 0.54
- neoplasm · score 0.51
- triple-negative breast cancer · score 0.51
- non-small cell lung carcinoma · score 0.42
- breast neoplasm · score 0.39
- bladder transitional cell carcinoma · score 0.26
- transitional cell carcinoma of kidney · score 0.26
- urogenital neoplasm · score 0.26
- ureter urothelial carcinoma · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P09758-F1 | alphafold | PREDICTED | 82.68 | — |
Amino-acid sequence (323 residues)
MARGPGLAPP PLRLPLLLLV LAAVTGHTAA QDNCTCPTNK MTVCSPDGPG GRCQCRALGS GMAVDCSTLT SKCLLLKARM SAPKNARTLV RPSEHALVDN DGLYDPDCDP EGRFKARQCN QTSVCWCVNS VGVRRTDKGD LSLRCDELVR THHILIDLRH RPTAGAFNHS DLDAELRRLF RERYRLHPKF VAAVHYEQPT IQIELRQNTS QKAAGDVDIG DAAYYFERDI KGESLFQGRG GLDLRVRGEP LQVERTLIYY LDEIPPKFSM KRLTAGLIAV IVVVVVALVA GMAVLVITNR RKSGKYKKVE IKELGELRKE PSL
Explore Tumor-associated calcium signal transducer 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets